https://hdl.handle.net/20.500.12328/14 2026-05-31T22:02:42Z 2026-05-31T22:02:42Z Casas, Francesc Vinolas Segarra, Nuria Ferrer, Ferrán Agusti Garcia Navarro, Carles Sánchez, Marcelo Gimferrer Garolera, Josep M Lomeña, Francisco Campayo, Marc Jeremic, Branislav https://hdl.handle.net/20.500.12328/5352 2026-05-29T16:48:08Z 2011-01-01T00:00:00Z

Long-Term Results of a Phase II Trial of Induction PaclitaxelCarboplatin Followed by Concurrent Radiation Therapy and Weekly Paclitaxel and Consolidation PaclitaxelCarboplatin in Stage III Non-small Cell Lung Cancer Casas, Francesc; Vinolas Segarra, Nuria; Ferrer, Ferrán; Agusti Garcia Navarro, Carles; Sánchez, Marcelo; Gimferrer Garolera, Josep M; Lomeña, Francisco; Campayo, Marc; Jeremic, Branislav Introduction: Long-term results of a phase II study on the use of induction chemotherapy (CHT) using paclitaxel (P)-carboplatin (C) followed by a concurrent radiation therapy (RT) and weekly P and consolidation PC were reviewed. Patients and Methods: Thirty-two patients with stage III non-small cell lung cancer started treatment with induction CHT (two cycles of P 175 mg/m2, day 1 and C, area under the curve 6, day 1, given at 3-week interval), after which accelerated RT with a concomitant boost (“field-in-a-field”) (1.8 Gy large fields and the boost dose 0.88 Gy) was administered in 23 fractions with 61.64 Gy and concurrent weekly P (45 mg/m2). Consolidation with two cycles of PC was administered. Results: The median follow-up for all 32 patients was 17.2 months (range, 3.8–107 months). The median survival time was 16.9 months, and the 5-year survival and 10-year survival were 25% and 17.5%, respectively. The median time for disease progression was 9.5 months, and disease-free survival was 21% at 5 and 10 years. The median time to local progression was 14.6 months, and the 5- to 10-year local progression-free survival was 35.7%. The median time to distant metastasis was 17.5 months. Toxicity was acceptable, with only one (3.1%) patient experiencing grade 5 (lung) toxicity and another patient presenting grade 4 toxicity (leucopenia). Conclusions: The results of this single-institutional phase II study of induction CHT followed by concurrent RT-CHT and consolidation CHT in very unfavorable patient population showed acceptable results with acceptable toxicity.

2011-01-01T00:00:00Z GRAU, JUAN-JOSE Caballero Borrego, Miguel MONZO, MARIANO Munoz, Patricia Domingo-Domenech, Josep Navarro, Alfons conill, carlos Campayo, Marc Bombí, Jose A. https://hdl.handle.net/20.500.12328/5351 2026-05-29T15:13:32Z 2008-08-01T00:00:00Z

Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy GRAU, JUAN-JOSE; Caballero Borrego, Miguel; MONZO, MARIANO; Munoz, Patricia; Domingo-Domenech, Josep; Navarro, Alfons; conill, carlos; Campayo, Marc; Bombí, Jose A. Background and Objectives: Single nucleotide polymorphisms of dihydropyrimidine dehydrogenases gene (DPYD) induces dihydropyrimidinedehydrogenase enzyme (DPD) deficiency resulting in increased activity of 5-fluorouracil derivatives. Cytidine-deaminase gene (CDA)polymorphisms have been involved in prognosis in experimental tumours.Methods: Analysis of 50 consecutive resected gastric cancer patients who received adjuvant chemotherapy with Tegafur for polymorphisms ofgenes DPYD1 (A/G; Ile543Val), DPYD2 (C/T; Arg29Cys) and CDA (A/C; Lys27Gin). The status of alleles (wild-type or at least onepolymorphism) was correlated with outcome and toxicity.Results: Polymorphisms frequencies wild-type/non-wild-type were 36/14 in DPYD1 (A/G; Ile543Val); 26/24 in DPYD2 (C/T; Arg29Cys); and 17/23 in CDA (A/C; Lys27Gin) or between homozygous/heterozygous were 39/11 in DPYD1; 33/17 in DPYD2 and 26/24 in CDA respectively. After77 months of median follow-up (SD ¼ 26.3), 18 patients died of tumour relapse. Better survival was observed in DPYD1 patients only, for non-wild-type over wild-type (P ¼ 0.0214); and in patients with one or more heterozygous polymorphisms in any of the three genes tested(P ¼ 0.0017). In 10 pts (20%) total dose was reduced by toxicity, only 3 of them were homozygous.Conclusions: Gene polymorphisms of DPYD and CDA predict survival of gastric cancer patients treated with 5-fluorouracil-based adjuvantchemotherapy.

2008-08-01T00:00:00Z Campayo, Marc Navarro, Alfons Vinolas Segarra, Nuria Díaz Sánchez, Tània Tejero-Villalba, Rut Gimferrer Garolera, Josep M Molins, Laureano Cabañas Leon, Maria Luisa Ramírez, Jose MONZO, MARIANO Marrades Sicart, Ramon https://hdl.handle.net/20.500.12328/5350 2026-05-29T16:58:23Z 2013-04-30T00:00:00Z

Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer Campayo, Marc; Navarro, Alfons; Vinolas Segarra, Nuria; Díaz Sánchez, Tània; Tejero-Villalba, Rut; Gimferrer Garolera, Josep M; Molins, Laureano; Cabañas Leon, Maria Luisa; Ramírez, Jose; MONZO, MARIANO; Marrades Sicart, Ramon ABSTRACT: The transcription factors SRY-related HMG box (SOX)2 and octamer-binding transcription factor (OCT)4 regulate the expression of the miR-302–367 cluster. miR-145 regulates SOX2 and OCT4 translation and p53 regulates miR-145 expression. We analysed the expression of the miR-302–367 cluster and miR-145 and the mutational status of p53 in resected nonsmall cell lung cancer (NSCLC) patients and correlated results with time to relapse (TTR). Tumour and paired normal tissue samples were obtained from 70 NSCLC patients. MicroRNA expression was assessed with TaqMan MicroRNA Assays. p53 exons 5 to 8 were sequenced. miR-145 was downregulated (p,0.0001) and miR-367 was upregulated (p,0.0001) in tumour compared with normal tissue. Mean TTR was 18.4 months forpatients with low miR-145 levels and 28.2 months for those with high levels (p50.015). Mean TTR was 29.1 months for patients with low miR-367 levels and 23.4 months for those with high levels (p50.048). TTR was shorter for patients with both unfavourable variables (p50.009). Low miR-145 expression (p50.049), the combination of unfavourable microRNA levels (p50.02) and the combination of low miR-145 with p53 mutations (p50.011) were independent markers of shorter TTR. In conclusion, miR-145 and miR-367 expression could be novel markers for relapse in surgically treated NSCLC. p53 may play a role in modulating miR-145 expression in NSCLC. This work was supported by grants from Fondo de Investigacio´n Sanitaria (FIS 080135, 09 00547), Sociedad Espan˜ola de Neumologı´ay Cirugı´a Tora´cica (SEPAR 809-2009) and Societat Catalana de Pneumologia (SOCAP 2009). T. Diaz is a fellow supported by Age`ncia de Gestio´ d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya and Fondo Social Europeo. R. Tejero is a fellow of the University of Barcelona.

2013-04-30T00:00:00Z GRAU, JUAN-JOSE Caballero Borrego, Miguel Campayo, Marc Sonia, Jansa Vargas, Mauricio Alos, Llucia MONZO, MARIANO https://hdl.handle.net/20.500.12328/5349 2026-05-29T16:59:54Z 2009-08-01T00:00:00Z

Gene Single Nucleotide PolymorphismAccumulation Improves Survival in Advanced Head and Neck Cancer PatientsTreated With Weekly Paclitaxel GRAU, JUAN-JOSE; Caballero Borrego, Miguel; Campayo, Marc; Sonia, Jansa; Vargas, Mauricio; Alos, Llucia; MONZO, MARIANO Objectives/Hypothesis: Single nucleotide polymorphisms (SNPs) of certain genes involved in drug metabolism correlate with survival. Methods: We evaluated the presence of SNPs in six genes (CYP2C8, GSTT1, GSTP1, MDR1-57, MDR1-62, and ERCC1) and the response rate (RR), time to progression (TTP), and overall survival (OS) of advanced head and neck cancer patients treated with weekly paclitaxel. Results: SNPs in CYP2C8, MDR1-57, and MDR1-62 genes were more frequent than wild-type genes in our patients. RR was 45% (21/47), and median TTP in responders was 5.1 months. OS for all patients was 5.6 months. Response was higher in SNPs of MDR1-62, MDR1-57, or in two or more accumulated genes than in those with wild-type genes. OS was significantly longer in patients with two or more accumulated SNPs (P = .039). Conclusions: Response rate and OS were significantly higher in patients with two or more accumulated SNPs.

2009-08-01T00:00:00Z